Sun Pharmaceutical Industries’ shares have surged in early trading after the company advanced its pursuit of a roughly $12 billion acquisition of US‑based women’s‑health specialist Organon & Co., marking one of the largest overseas deals ever contemplated by an Indian drugmaker. The optimism around the Organon transaction sent Sun Pharma’s scrip sharply higher, making it one of the top gainers on the Nifty 50 index and drawing fresh attention from institutional and retail investors.

According to reports, Sun Pharma has moved to the final stages of preparing a binding offer for Organon, completing extensive due diligence over several months and now finalising a financing package to back the all‑cash deal. The proposed $12 billion bid would significantly expand Sun’s presence in the US, particularly in women’s health, biosimilars, and specialty brands, while giving the Indian firm access to Organon’s established product pipeline and regulatory footprint in a key Western market.

Despite the buzz around the acquisition, Sun Pharma has publicly clarified that it has not yet entered into any definitive agreement with Organon, and the deal remains contingent on board approvals, regulatory clearances, and satisfactory financing terms. The company’s official response to bourse queries stressed that there is “no final or actionable development” yet, even as the market rewards the prospect of such a large strategic move in the global pharma landscape.

Also Read: Stock Market Today: Key Updates, Global Trends And Cues For April 27

In the broader market, Sun Pharma already ranks among the stronger performers in the Nifty 50, benefiting over the past year from robust earnings growth, improving balance‑sheet metrics, and sustained investor appetite for Indian‑listed pharma names. The Organon speculation adds a fresh layer of value‑creation potential, as analysts see the deal as a potential game‑changer for India’s pharma sector if it is successfully executed without over‑leveraging the balance sheet.

Investors watching Sun Pharma’s stock are now weighing the trade‑off between the long‑term upside of a blockbuster overseas acquisition and the short‑term risks of integration complexity and financing costs. For now, the market’s reaction suggests that many see the Organon play as a bullish signal, positioning Sun Pharma not just as a generic‑drug workhorse but as a more diversified, innovation‑oriented global player increasingly central to India’s presence in the world pharma ecosystem.

Also Read: Rs 50,000 Salary EPF Contributions Can Build Over Rs 2.9 Crore Retirement Fund